TY - JOUR
T1 - Antibiotic prescribing before and after the diagnosis of comorbidity
T2 - A cohort study using primary care electronic health records
AU - Rockenschaub, Patrick
AU - Hayward, Andrew
AU - Shallcross, Laura
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background. Comorbidities such as diabetes and chronic obstructive pulmonary disease (COPD) increase patients' susceptibility to infections, but it is unclear how the onset of comorbidity impacts antibiotic use. We estimated rates of antibiotic use before and after diagnosis of comorbidity in primary care to identify opportunities for antibiotic stewardship. Methods. We analyzed UK primary care records from the Clinical Practice Research Datalink. Adults registered between 2008-2015 without prior comorbidity diagnoses were eligible for inclusion. Monthly adjusted rates of antibiotic prescribing were estimated for patients with new-onset stroke, coronary heart disease, heart failure, peripheral arterial disease, asthma, chronic kidney disease, diabetes, or COPD in the 12 months before and after diagnosis and for controls without comorbidity. Results. 106 540/1 071 943 (9.9%) eligible patients were diagnosed with comorbidity. Antibiotic prescribing rates increased 1.9- to 2.3-fold in the 4-9 months preceding diagnosis of asthma, heart failure, and COPD before declining to stable levels within 2 months after diagnosis. A less marked trend was seen for diabetes (rate ratio, 1.55; 95% confidence interval, 1.48-1.61). Prescribing rates for patients with vascular conditions increased immediately before diagnosis and remained 30%-39% higher than baseline afterwards. Rates of prescribing to controls increased by 17%-28% in the months just before and after consultation. Conclusions. Antibiotic prescribing increased rapidly before diagnosis of conditions that present with respiratory symptoms (COPD, heart failure, asthma) and declined afterward. Onset of respiratory symptoms may be misdiagnosed as infection. Earlier diagnosis of these comorbidities could reduce avoidable antibiotic prescribing.
AB - Background. Comorbidities such as diabetes and chronic obstructive pulmonary disease (COPD) increase patients' susceptibility to infections, but it is unclear how the onset of comorbidity impacts antibiotic use. We estimated rates of antibiotic use before and after diagnosis of comorbidity in primary care to identify opportunities for antibiotic stewardship. Methods. We analyzed UK primary care records from the Clinical Practice Research Datalink. Adults registered between 2008-2015 without prior comorbidity diagnoses were eligible for inclusion. Monthly adjusted rates of antibiotic prescribing were estimated for patients with new-onset stroke, coronary heart disease, heart failure, peripheral arterial disease, asthma, chronic kidney disease, diabetes, or COPD in the 12 months before and after diagnosis and for controls without comorbidity. Results. 106 540/1 071 943 (9.9%) eligible patients were diagnosed with comorbidity. Antibiotic prescribing rates increased 1.9- to 2.3-fold in the 4-9 months preceding diagnosis of asthma, heart failure, and COPD before declining to stable levels within 2 months after diagnosis. A less marked trend was seen for diabetes (rate ratio, 1.55; 95% confidence interval, 1.48-1.61). Prescribing rates for patients with vascular conditions increased immediately before diagnosis and remained 30%-39% higher than baseline afterwards. Rates of prescribing to controls increased by 17%-28% in the months just before and after consultation. Conclusions. Antibiotic prescribing increased rapidly before diagnosis of conditions that present with respiratory symptoms (COPD, heart failure, asthma) and declined afterward. Onset of respiratory symptoms may be misdiagnosed as infection. Earlier diagnosis of these comorbidities could reduce avoidable antibiotic prescribing.
KW - Antibiotic
KW - Antimicrobial stewardship
KW - Comorbidity
KW - Primary care
UR - http://www.scopus.com/inward/record.url?scp=85084970449&partnerID=8YFLogxK
U2 - 10.1093/cid/ciz1016
DO - 10.1093/cid/ciz1016
M3 - Article
C2 - 31631225
AN - SCOPUS:85084970449
SN - 1058-4838
VL - 71
SP - E50-E57
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 7
ER -